Middle East & Africa Sepsis Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Technology, Method, Test Type, Pathogen, and End User

The MEA sepsis diagnostics market is expected to grow from US$ 19.20 million in 2021 to US$ 33.35 million by 2028; it is estimated to grow at a CAGR of 8.2% from 2021 to 2028.

Technology is a critical parameter in healthcare diagnostics to provide accuracy and save time and resources.In the process of sepsis diagnosis, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment.

Molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology are majorly used sepsis diagnostics techniques.Among all, molecular diagnostics (MDx) is an attractive approach to consider for sepsis diagnostics.

The increasing adoption of molecular diagnostic technology due to its several advantages, such as high sensitivity, accuracy, and less turnaround time, over other technologies has proved it the gold standard.Therefore, several companies are investing in point-of-care molecular diagnostics to diagnose bacterial and viral pathogens early and for better patient management.

This test is one of the first rapid, fully integrated, and immune response-based tests to aid clinicians with a sepsis diagnosis. Thus, the rising use of technology, such as molecular diagnostics, in sepsis diagnosis is a crucial trend followed by emerging key players operating in the market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets.This factor is likely to drive the MEA sepsis diagnostics market.

The MEA sepsis diagnostics market is expected to grow at a good CAGR during the forecast period.

MEA Sepsis Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

MEA Sepsis Diagnostics Market Segmentation

The MEA sepsis diagnostics market is segmented based on product, technology, method, test type, pathogen, end user, and country.Based on product, the MEA sepsis diagnostics market is divided into instruments, reagents and assays, blood culture media, and software.

The blood culture media dominated the MEA sepsis diagnostics market in 2021.Based on technology, the MEA sepsis diagnostics market is categorized into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology.

The microbiology segment dominated the MEA sepsis diagnostics market in 2021.Based on method, the MEA sepsis diagnostics market is categorized into automated diagnostics and conventional diagnostics.

The conventional diagnostics segment dominated the MEA sepsis diagnostics market in 2021. Based on test type, the MEA sepsis diagnostics market is categorized into point-of-care tests and laboratory tests. The laboratory tests segment dominated the MEA sepsis diagnostics market in 2021. Based on pathogen, the MEA sepsis diagnostics market is categorized into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment dominated the MEA sepsis diagnostics market in 2021. Based on end user, the MEA sepsis diagnostics market is categorized into hospitals, pathology and reference laboratories, and others. The hospitals segment dominated the MEA sepsis diagnostics market in 2021. Based on country, the MEA sepsis diagnostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of MEA. Saudi Arabia dominated the MEA sepsis diagnostics market in 2021.

Key players operating in the MEA sepsis diagnostics market include Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; THERMO FISHER SCIENTIFIC INC.; bioMerieux SA; and T2 Biosystems, Inc. by Altair.